News

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Careful management of patient expectations is key to achieving optimal outcomes.

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with GA in dry AMD.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

MHRA issues precautionary recall for Zaditen eye drops due to potential microbial contamination risk

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Boehringer Ingelheim initiates the THULITE study, exploring an oral treatment for diabetic macular edema.

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable implant injected intravitreally every 6 months.

The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

A new study links urinary metabolites from organophosphorus pesticides to increased age-related macular degeneration risk.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

New technologies and a proactive mindset are transforming how glaucoma is diagnosed and treated—and redefining what “controlled” really means.

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights into both ocular and systemic diseases.

In addition to Prevent Blindness' usual free resources, the organization is providing a dedicated web page, fact sheets, and graphics in English and Spanish.

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.

Yesafili is the first biosimilar to Eylea to be approved by Health Canada.

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop to treat people with neurotrophic keratitis.

All 696 patients in the trial have completed their treatment and follow-up visits.

Patients express mixed feelings about AI in health care, favoring its use for documentation and administrative tasks while demanding transparency and safety standards.